Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2004

01-06-2004 | Case Report

Splenic marginal zone B-cell lymphoma associated with primary Sjögren’s syndrome

Authors: Susumu Nishiyama, Shoji Miyawaki

Published in: Clinical Rheumatology | Issue 3/2004

Login to get access

Abstract

We describe a 67-year-old woman with primary Sjögren’s syndrome who developed a splenic marginal zone B-cell lymphoma, and complained of a dry mouth and Raynaud’s phenomenon. She had splenomegaly, swollen lymph nodes and monoclonal IgM-κ cryoglobulin. After splenectomy, Raynaud’s phenomenon had improved with the decrease of cyroglobulin. This is the first case of primary Sjögren’s syndrome with splenic marginal zone B-cell lymphoma to be reported.
Literature
1.
Harris NL, Jaffe ES, Diebold J et al. (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193–207PubMed
2.
Kassan SS, Thomas TL, Moutsopoulos HM et al. (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89:888–892PubMed
3.
Kohler PF, Winter ME (1985) A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum 28:1128–1132PubMed
4.
Miyawaki S, Tojo T (1994) Sjögren’s syndrome: state of the art. Kugler, Amsterdam, pp 77–79
5.
Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjögren’s syndrome. Arthritis Rheum 42:1765–1772CrossRefPubMed
6.
Royer B, Cazals-Hatem D, Sibilia J et al. (1997) Lymphomas in patients with Sjögren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, are not associated with viruses. Blood 90:766–775PubMed
7.
Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V (2001) The cryoglobulins: an overview. Eur J Clin Invest 31:628–638CrossRefPubMed
8.
Cuéllar ML, García C, Molina JF (1995) Cryoglobulinemia and other dysproteinemias, familial Mediterranean fever, and POEMS syndrome. Curr Opin Rheumatol 7:58–64PubMed
Metadata
Title
Splenic marginal zone B-cell lymphoma associated with primary Sjögren’s syndrome
Authors
Susumu Nishiyama
Shoji Miyawaki
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0838-7

Other articles of this Issue 3/2004

Clinical Rheumatology 3/2004 Go to the issue

Letter

Quality of marital life in patients with spondyloarthropathy

Letter to the Editor

Lateral epicondylitis with marked soft tissue swelling in spondyloarthritis

Original Article

Bone mineral density in children with familial Mediterranean fever

Case Report

Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis

Book Review

Frank McKenna, Lee S. Simon: Rapid Reference to Arthritis

Original Article

Increased serum levels of interleukin-8 in polyarteritis nodosa and Behçet’s disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits